Simultaneous quantification of losartan and active metabolite in human plasma by liquid chromatography–tandem mass spectrometry using irbesartan as internal standard

Losartan

“…Prasaja et al [44] developed a liquid chromatography-tandem mass spectrometry (LC-MS/MS) method employing electrospray ionization for quantification of losartan and its carboxylic acid metabolite in human plasma using irbesartan as IS. Following a simple pretreatment procedure, the analytes were separated using a gradient mobile phase on reverse-phase C18 column.…”

Liquid chromatography–mass spectrometric determination of losartan and its active metabolite on dried blood spots

“…Several analytical methods were reported in the literature for analysis of LOS and LCA in plasma [53][54][55][56][57][58][59][60][61]; which include HPLC with UV [53], fluorescence [54,55] and mass spectrometry [56][57][58][59][60][61] as detectors. Sample treatment is usually carried out by solid phase extraction (SPE) [4,[56][57][58][59][60][61].…”

“…Sample treatment is usually carried out by solid phase extraction (SPE) [4,[56][57][58][59][60][61]. To the best of authors' knowledge no work has been published for analysis of LOS and its active metabolite on DBS.…”

A New HPLC Method for Determination of Losartan in Human Plasma and its Application in Bioequivalence Studies

“…Losartan should be administered orally once or twice daily for a total daily dose of 25-100 mg. 3 Last studies showed that several HPLC ,LC/MS/MS methods were used for determination of losartan and its metabolite in human plasma. [4][5][6][7][8][9][10][11][12] The aim of this study was to develop a simple, rapid sensitive and reliable HPLC method with Ultraviolent detection for quantization of losartan in human plasma samples and to compare the bioavailability of two losartan tablets (50 mg) formulations (losartan from Iranian company, as a test formulation and COZAR, MSD ,The Netherlands as a reference formulation) . The method was validated according to procedures and acceptance criteria based on FDA guideline and recommendations of ICH, to provide enough selectivity, sensitivity and reliability in pharmacokinetic and bioequivalence studies.…”